Transcriptional suppression of Dicer by HOXB‐AS3/EZH2 complex dictates sorafenib resistance and cancer stemness

Sorafenib is a multikinase inhibitor for the standard treatment of advanced liver cancer patients. However, acquired resistance to sorafenib is responsible for a poor prognosis. Therefore, uncovering the molecular mechanisms underlying sorafenib sensitization can provide biomarkers for sorafenib tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Chi‐Feng, Chen, Li‐Tzong, Wang, Horng‐Dar, Liu, Yi‐Hong, Shiah, Shine‐Gwo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128169/
https://www.ncbi.nlm.nih.gov/pubmed/35253323
http://dx.doi.org/10.1111/cas.15319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128169/
https://www.ncbi.nlm.nih.gov/pubmed/35253323
http://dx.doi.org/10.1111/cas.15319

Ejemplares similares